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Objective To report outcomes in a recent series of pregnancies
in women with Marfan syndrome (MFS).
Design Retrospective case note review.
Setting Tertiary referral unit (Chelsea and Westminster and Royal
Brompton Hospitals).
Sample Twenty-nine pregnancies in 21 women with MFS between
1995 and 2010.
Methods Multidisciplinary review of case records.
Main outcome measures Maternal and neonatal mortality
and morbidity of patients with MFS and healthy controls.
Results There were no maternal deaths. Significant cardiac
complications occurred in five pregnancies (17%): one woman
experienced a type–A aortic dissection; two women required
cardiac surgery within 6 months of delivery; and a further two
women developed impaired left ventricular function during the
pregnancy. Women with MFS were also more likely to have
obstetric complications (OR 3.29, 95% CI 1.30–8.34), the most
frequent of which was postpartum haemorrhage (OR 8.46,
95% CI 2.52–28.38). There were no perinatal deaths, although
babies born to mothers with MFS were delivered significantly
earlier than those born to the control group (median 39 versus
40 weeks of gestation, Mann–Whitney U–test, P = 0.04). These
babies were also significantly more likely to be small for
gestational age (24% in the MFS group versus 6% in the controls;
OR 4.95, 95% CI 1.58–15.55).
Conclusions Pregnancy in women with MFS continues to be
associated with significant rates of maternal, fetal, and neonatal
complications. Effective pre-pregnancy counselling and meticulous
surveillance during pregnancy, delivery, and the puerperium by an
experienced multidisciplinary team are warranted for women with
MFS.
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Introduction
Marfan syndrome (MFS) is a hereditary multisystem con-
nective tissue disorder with autosomal dominant inheri-
tance, affecting approximately 1 in 5000 of the population.1
It is caused by a mutation in the fibrillin–1 gene (FBN1)
on chromosome 15q21, although heterozygous mutations
in the tissue growth factor–B receptor 2 (TGFBR2) gene on
chromosome 3p24.2–25 have also been identified in other
Marfan-like syndromes.2 Diagnosis is based on the 2010
revised Ghent nosology.1 Eighty percent of patients will
have some cardiovascular involvement (including aortic
dilatation, aortic incompetence, and mitral or tricuspid
valve prolapse, with or without regurgitation), with abnor-
malities of the skeletal and ocular systems being the other
prominent manifestations.3 The major causes of death
remain aortic aneurysm rupture and dissection.4
Normal pregnancy is associated with dilatation of the
aorta and increased aortic compliance.5,6 A reduction in
mucopolysaccharides in the aortic wall has also been
documented.7 These factors, in combination with the hae-
modynamic changes of pregnancy, may contribute to the
increased risk of aortic dissection.8,9 Recent guidelines sug-
gest a 1% risk of aortic dissection or significant cardiac
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event in women with an aortic root diameter of <40 mm.10
This risk is increased when the aortic root diameter is
>40 mm, if there is a rapid increase in aortic dimensions, or
in the context of a family history of dissection.11 Body sur-
face area is also important, particularly in women of short
stature: an aortic diameter index of >27 mm/m2 is associated
with an increased risk of dissection, and prophylactic surgery
should be considered.10 The risk factors for distal dissection
are less well characterised. Additionally, aortic dissection
may occur even in the absence of dilatation.12
Fibrillin–1 is present in the myocardium, where abnor-
malities of its structure may predispose patients with MFS
to left ventricular (LV) dilatation and impairment of LV
function, even in the absence of valvular pathology,13–15
although such an effect has not yet been described in preg-
nancy.
Marfan syndrome may also be associated with an
increase in obstetric complications, including preterm
delivery, preterm prelabour rupture of membranes, cervical
incompetence, poor fetal outcome, and postpartum haem-
orrhage.16–19 We have performed a retrospective case note
review to assess maternal and neonatal outcomes in women
with MFS. In addition, we report on two cases where dete-
rioration in LV function occurred during pregnancy in
women with MFS.
Methods
Women with a diagnosis of MFS, cared for by the Joint
Cardiac and Obstetric Service of the Chelsea and Westmin-
ster and Royal Brompton Hospitals, were identified from a
database commenced in 1994. Only singleton pregnancies
progressing beyond 24 weeks of gestation were included.
For each woman with MFS there were four controls: two
women who delivered immediately before and two women
who delivered immediately after each index case. This
allowed comparison with our overall population, while
controlling for changes in demographics and practice over
time. Four women with MFS delivered before 1998, and
because data for control women were not available before
this date, women who delivered on the same date in 1999
were used as controls.
Data were collected from a detailed review of case notes
supplemented by the Ciconia Maternity Information Sys-
tem (CMIS©, HD Clinical Ltd, Bishops Stortford, Herts,
UK). In all women baseline data (including age at booking,
parity, comorbidities, regular medication, and previous car-
diac surgery), obstetric and anaesthetic management during
pregnancy and labour, and maternal and neonatal out-
comes was obtained, noting cardiac, obstetric, and fetal/
neonatal complications classified according to the following
definitions.
Cardiac complications
Aortic dissection; increase in aortic root diameter, worsen-
ing mitral or aortic regurgitation, as seen at echocardiogra-
phy; myocardial infarction; pulmonary oedema; arrhythmia;
endocarditis; cardiac death; aortic surgery within 6 months
of delivery.
Obstetric complications
Antepartum haemorrhage (APH – bleeding from the geni-
tal tract after 24 weeks of gestation); pregnancy-induced
hypertension (PIH – raised blood pressure >140/90 mmHg
after 20 weeks of gestation); pre-eclampsia (PIH criteria
with proteinuria of >300 mg/l in a 24–hour urine collec-
tion or persistent ++ proteinuria); eclampsia (pre-eclamp-
sia with major convulsive seizures); gestational diabetes;
preterm prelabour rupture of membranes (PPROM – spon-
taneous rupture of membranes prior to 37 weeks of gesta-
tion in the absence of regular painful contractions);
preterm labour (labour prior to 37 weeks of gestation);
postpartum haemorrhage (PPH – blood loss greater than
500 ml at vaginal delivery or 1000 ml at caesarean section);
and thromboembolism.
Fetal/neonatal complications
Preterm birth (delivery after 24 and before 37 completed
weeks of gestation); small for gestational age (SGA –
birthweight less than fifth customised centile); respiratory
distress syndrome (RDS); intraventricular haemorrhage
(IVH); fetal demise (intrauterine death after 20 weeks of
gestation); perinatal mortality (stillbirth after 24 com-
pleted weeks of pregnancy and neonatal death up to
1 week after birth); neonatal mortality (up to 1 month of
life).
Additionally, in the Marfan group data on the aortic
root diameter pre-pregnancy (as measured at echocardiog-
raphy), and LV dimensions and function and aortic root
diameter during pregnancy (at serial echocardiographic
assessments) were gathered. The aortic root diameters were
measured at the four standard levels (‘annulus’, sinus of
valsalva, sinotubular junction, and ascending aorta) in all
cases.
Data were analysed using SPSS 18 for windows. Differ-
ences in outcomes between the Marfan and control groups,
and between first and subsequent pregnancies in the
Marfan group, were evaluated. Continuous variables were
compared with the Students t–test if data were normally
distributed and with the Mann–Whitney U–test if they
were not. The chi-square test or Fisher’s exact test with
cell numbers of <5 were used to test differences between
relative frequencies of occurrence. All tests were
two-tailed and P < 0.05 was considered statistically
significant.
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The echocardiographic data could not be analysed simply
by combining all the measurements, as this would create
an ascertainment bias (those with any observed deteriora-
tion would be more likely to have more scans and therefore
contribute disproportionately to the results). We therefore
analysed each case with at least two echocardiograms more
than 6 weeks apart by calculating a regression line of each
echocardiographic parameter measured against gestational
age, and deriving from it the predicted measurement at 12,
28, and 36 weeks of gestation, so that each subject
contributed three values to the pooled results. This also
had the advantage of smoothing some of the interobserver
variability.
Customised birthweight centiles, adjusted for gestational
age, gender, parity, maternal body mass index (BMI) and racial
group, were calculated using computer-generated charts.20,21
This study received approval from the Brompton, Hare-
field, and National Heart and Lung Institute (NHLI)
Research Ethics Committee (ref. no. 06/Q0404/37).
Results
Twenty-nine pregnancies in 21 women with MFS were com-
pared with 116 controls. Their baseline characteristics are
shown in Table 1. There was no statistically significant dif-
ference in age or parity between the two groups (P = 0.10
and 0.19, respectively). The mean age at booking in the MFS
group was 31.1 years (range 17–42 years), compared with
32.8 years (range 17–43 years) in the control group. Mater-
nal and fetal/neonatal outcomes in nulliparous (n = 21) and
parous (n = 8) women with MFS were similar (Table 2).
Cardiac outcomes
There were three pregnancies in women with MFS who
had undergone cardiac surgery prior to pregnancy: two of
these had valve-sparing aortic root replacement, and one
had both the aortic root and the valve replaced.
Sequential echocardiography data from 11 pregnancies
(Figures 1–4) were available for analysis, as described previ-
ously, and showed no significant change in either aortic
root diameter or LV dimensions and function during preg-
nancy. The mean aortic root diameter pre-pregnancy was
39.5 mm (median 40 mm, range 26–81 mm); in 12 preg-
nancies it was greater than 40 mm. The mean increase in
aortic root diameter during pregnancy was 0.47 mm (med-
ian 0.40 mm, range 0.00–0.90 mm), although upon regres-
sion analysis this change was not statistically significant.
Beta-blockers (thought to confer some protection against
long-term dilatation of the aortic root) were taken
throughout 26 pregnancies (two of the three pregnancies
where a beta-blocker was not taken were in women with
an aortic root >40 mm).2,22–24
Table 1. Baseline characteristics, mode of delivery, use of
anaesthesia, birthweight and birthweight centiles, and complications
in women with MFS and in control women
MFS Controls
Number of
women
21 116
Number of
pregnancies
29 116
Mean
(SD)
Mean
(SD)
Age at booking
(years)
31.1 (5.0) 32.8 (5.5) P = 0.1
Maternal height
(cm)
179 SD 8.7 164 SD 7.7 P < 0.0001
Median
(range)
Median
(range)
Maternal weight
(kg)
69
(49–120)
60
(45–102)
P = 0.007
n (%) n (%)
Parity
Nulliparous 21 (72) 69 (59)
Para 1–5 8 (28) 47 (41)
Mode of delivery
Spontaneous vaginal
delivery
5 (17) 71 (61) OR 0.13
(0.04–0.37)
Assisted vaginal
delivery
12 (41) 15 (13) OR 4.75
(1.9–11.9)
Elective caesarean section 9 (31) 24 (21)
Emergency caesarean
section
3 (11) 6 (5)
Regional anaesthesia
for vaginal delivery
13 (76) 40 (47) OR 3.7
(1.13–12.39)
Median
(range)
Median
(range)
Length of second
stage (mins)
67
(7–136)
30.5
(4–187)
P = 0.07
Gestational age at
delivery (weeks)
39
(35–42)
40
(27–42)
P = 0.04
Mean (SD) Mean (SD)
Birthweight (g) 3068 (471) 3324 (505) P = 0.007
Median
(range)
Median
(range)
Customised birthweight
centile
29 (0–92) 49 (0–100) P = 0.001
n (%) n (%)
Distribution of birthweight centiles
90–100 2 (7) 11 (10)
75–89 0 (0) 20 (17)
50–74 6 (21) 25 (22)
25–50 4 (13) 34 (29)
10–24 6 (21) 12 (10)
0–9 11 (38) 14 (12)
Obstetric
complications
10 (34) 16 (14) OR 3.29
(1.30–8.34)
PPH 8 (28) 5 (4) OR 8.46
(2.52–28.38)
Neonatal
complications
9 (31) 12 (10) OR 3.9
(1.45–10.47)
SGA 7 (24) 7 (6) OR 4.95
(1.58–15.55)
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There were no maternal deaths; however, significant
cardiac complications occurred in five pregnancies (17%).
One woman experienced a type–A aortic dissection 10 days
post-delivery, requiring emergency root and valve replace-
ment. Two women required cardiac surgery within
6 months of delivery: one required aortic replacement on
the seventh postnatal day because of increasing dilatation
of the aortic root (from 81 mm pre-pregnancy to
89 mm)25; the other woman underwent aortic root and
valve replacement 6 months postnatally for worsening
Table 2. Comparison of first and second pregnancies in women
with MFS
First
pregnancy
Second
pregnancy
Number of pregnancies 21 8
Mean (SD) Mean (SD)
Maternal age at
booking
30.19 (5.4) 33.5 (2.3) P = 0.03
Maternal height (cm) 178 (8.7) 180 (8.9) P = 0.55
Median
(range)
Median
(range)
Maternal weight (kg) 63 (49–120) 71 (59–120) P = 0.21
n (%) n (%)
Mode of delivery
SVD 3 (14) 2 (25)
Assisted vaginal delivery 9 (43) 3 (38)
Elective CS 7 (33) 2 (25)
Emergency CS 2 (10) 1 (12)
Median
(range)
Median
(range)
Gestational age at
delivery (weeks)
39.1 (35–42) 38.4 (37–40) P = 0.19
Mean (SD) Mean (SD)
Birthweight (g) 2995 (476.8) 3258 (430.1) P = 0.18
Birthweight centile 25.2 (25.8) 40.5 (36.9) P = 0.31
Aortic root
pre-pregnancy (mm)
39 (1.3) 40 (0.5) P = 0.86
n (%) n (%)
Cardiac complications 4 (19) 1 (12)
Obstetric complications 7 (33) 3 (38)
Neonatal complications 7 (33) 2 (25)
Figure 1. Echocardiographic measurement of left ventricular diastolic
dimensions during pregnancy in women with MFS. Data for women
who developed LV dysfunction are plotted in red.
Figure 2. Echocardiographic measurement of LV systolic dimensions
during pregnancy in women with MFS. Data for women who
developed LV dysfunction are plotted in red.
Figure 3. Echocardiographic measurement of fractional shortening
during pregnancy in women with MFS. Data for women who
developed LV dysfunction are plotted in red.
Figure 4. Echocardiographic measurement of ejection fraction during
pregnancy in women with MFS. Data for women who developed LV
dysfunction are plotted in red.
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aortic regurgitation. A further two women developed
impaired LV function during the pregnancy (Figures 3
and 4).
Obstetric outcomes
Fifty-nine percent (17) of the index pregnancies resulted in
vaginal delivery, compared with 74% (86) of the control
pregnancies (P = 0.11); however, births in women in the
MFS group who delivered vaginally were more likely to be
assisted (using forceps or ventouse) than those in the
control group [71% (12/17) and 17% (15/86), respectively;
OR 11.36, 95% CI 3.48–37.08], as assisted delivery was rec-
ommended policy for women with MFS unless they had a
very short second stage (women with a pre-pregnancy aor-
tic root >40 mm underwent elective assisted delivery).
Despite this policy, the second stage appeared to be longer
in the MFS group (median 67 minutes, range 7–136 min-
utes, in the MFS group versus 30.5 minutes, range
4–187 minutes, in the control group; P = 0.07), although
the difference did not quite reach statistical significance.
There was no statistically significant difference in the over-
all caesarean section rate [12/29 (41%) in the MFS group
versus 30/116 (26%) in the control group; P = 0.11], and
the proportions of elective versus emergency caesarean sec-
tion were also similar (P = 0.32 and 0.65, respectively).
Nine of the caesarean sections in the MFS group were per-
formed for obstetric reasons (one emergency and eight
elective) and three for cardiac reasons (all elective for pro-
gressive aortic root dilatation or deteriorating LV function).
Of the pregnancies in the MFS group that resulted in vaginal
delivery, 13 (76%) had regional anaesthesia compared with
40 (47%) of the controls (OR 3.7, 95% CI 1.13–12.39). Of
those that ended in caesarean section two women (16%) in
the MFS group required general anaesthesia compared with
two women (7%) in the control group (P = 0.56).
The risk of obstetric complications was significantly
higher in the MFS group (OR 3.29, 95% CI 1.30–8.34),
with obstetric complications occurring in ten (34%) preg-
nancies. One woman developed PIH, one woman had a
significant APH, and eight women had PPH (defined as
an estimated blood loss of greater than 500 ml at vaginal
delivery and greater than 1000 ml at caesarean section). In
the control group, 16 (14%) women had obstetric compli-
cations: one woman developed PIH; five women developed
pre-eclampsia (PET); one woman had significant APH; five
women had PPH; and four women experienced spontaneous
preterm labour. In particular, the women with MFS were
more at risk of PPH (OR 8.46, 95% CI 2.52–28.38).
Fetal and neonatal outcomes
There were no fetal or neonatal deaths, but complications
were more likely in the MFS group (OR 3.9, 95% CI 1.45–
10.47). The median gestational age at delivery in the MFS
group was 39 weeks (range 35–42 weeks), significantly ear-
lier than in the control group (median 40 weeks, range 27–
42 weeks; P = 0.04, Mann–Whitney U-test). Preterm
(before 37 completed weeks of gestation) delivery rates
were similar in both groups. Of the babies born to mothers
with MFS, 2 (7%) were delivered preterm compared with 5
(4%) of those with unaffected mothers. Both of the pre-
term babies in the MFS group were delivered iatrogenically
early for maternal reasons, compared with only one of the
five preterm babies in the control group. Mean and median
birthweight and birthweight centile were lower in the MFS
group: 3068 g (median 3030 g, range 2300–3900 g), 29th
centile (median 20, range 0–92), versus 3324 g (median
3380 g, range 920–4450 g), 49th centile (median 48, range
0–100) in the control group (Student’s t-test, P = 0.007;
and Mann–Whitney U–test, P = 0.001). The babies in the
MFS group were also more likely to be small for gestational
age (SGA – birthweight less than the fifth centile), with
seven (24%) of the babies in the MFS group being SGA
compared with seven (6%) of those born in the control
group (OR 4.29; 95% CI 1.58–15.55). Additionally, in the
MFS group there was an inverse relationship between
birthweight and maternal height (Figure 5). Six of the babies
born to index cases were subsequently diagnosed with MFS
following genetic testing, with ten found to be unaffected. In
13 babies the diagnosis of MFS has not yet been proven or
refuted. No other congenital abnormalities were detected.
Discussion
Main findings
In our series of 29 pregnancies in 21 women with MFS
there were no maternal or perinatal deaths. There were,
Figure 5. Relationship between maternal height and birthweight in
women with MFS.
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however, more maternal and fetal complications compared
with healthy controls. Significant cardiovascular complica-
tions occurred in five MFS pregnancies (17%): LV dysfunc-
tion developed in two women; there was one case of aortic
dissection (requiring emergency surgery); and two women
required cardiovascular surgery within 6 months of delivery
(aortic root replacement on the seventh postnatal day for
increasing aortic root dilatation, from 81 mm pre-preg-
nancy to 89 mm, in one woman25; and aortic root and
valve replacement 6 months postnatally for worsening aor-
tic regurgitation in the other woman). The caesarean sec-
tion rate was 42% in the MFS group compared with 26%
in the control group (not statistically significant, although
there was a trend towards a higher rate in the index
group). The risk of PPH was significantly increased in
women with MFS (OR 8.46, 95% CI 2.52–28.38). The
median gestational age at delivery in the MFS group was
39 weeks (range 35–42 weeks), significantly earlier than in
the control group (median 40 weeks, range 27–42 weeks;
Mann–Whitney U-test, P = 0.04); however, the number of
preterm births was not significantly different (three and
five, respectively). Babies in the MFS group were more
frequently SGA (24 versus 6%). Additionally, in the MFS
group there was an inverse relationship between birth-
weight and maternal height (contrary to normal pregnan-
cies, where taller mothers tend to have bigger babies).
Outcomes in second pregnancies were similar to those in
the first pregnancy (Table 2).
Strengths
The women in our series were managed by the same core
team over the period of the study. Relevant data were
recorded contemporaneously in our database. Our data
reflect current clinical practice, whereby most women were
fully evaluated and counselled before pregnancy. All pre-
senting cases have been reported so the cohort is of a con-
tinuous series. We had an appropriate control population
managed in the same maternity unit.
Weaknesses
The cohort of patients studied reflects patients under the care
of the Royal Brompton and Chelsea and Westminster hospi-
tals, and therefore a referral bias is possible, if not likely. Our
analysis was retrospective and with the exception of aortic
dissection, outcome measures were not pre-specified.
Comparison with similar studies
Early cohort studies such as that of Pyeritz et al.16 did not
report aortic dissection as a complication of pregnancy. The
maternal complication rate in our series was similar to that
reported for the cohort described by Lipscomb et al.; how-
ever, they did not find an increase in PPH (seven cases in 75
pregnancies), and furthermore made no mention of an
increase in the likelihood of babies being SGA.26 In 2001
Lind and Wallenburg reported five dissections in 78 preg-
nancies.27 By contrast, in a review of 111 pregnancies beyond
20 weeks of gestation, Meijboom et al. reported only one
pregnancy-related aortic dissection; the rate of lifetime dis-
section in their series was 36% in both women who had been
pregnant and women who remained nulligravid.17 They
reported a 15% incidence of preterm birth, but only a 6%
rate of SGA below the fifth centile. In contrast to these two
cohorts, Katsuragi et al., describing a cohort of Japanese
patients in 2011, reported that 11/28 experienced aortic dila-
tation or dissection (seven during pregnancy and four
post-delivery).28 This may have been because their National
Cardiovascular Center accepted patients specifically referred
for cardiac complications. The same authors reported early
delivery (mean 36.8 weeks of gestation) and corresponding
low birthweight (mean 2750 g, compared with a mean of
3068 g in our cohort), but this may be because of early inter-
vention for maternal complications (no data on the caesar-
ean section rate was given), and/or because of smaller body
habitus amongst Japanese versus UK individuals.
Interpretation: mechanisms, and implications for
clinicians and policymakers
Our study reinforces the increased risk of cardiovascular
complications in women with MFS during pregnancy.
European guidelines suggest that women with minimal car-
diovascular involvement and an aortic root diameter of
<40 mm have an estimated risk of 1% of dissection or
other serious cardiovascular complications; this may be
greater in women at high risk (aortic root diameter
>40 mm, rapid aortic dilatation, or previous dissection).10
In our series the five patients who experienced serious car-
diovascular complications had pre-pregnancy aortic root
diameters in excess of 40 mm (the mean pre-pregnancy
aortic root diameter was 39.5 mm and in 12 women it was
greater than 40 mm, suggesting a particularly high-risk
population).
Elective aortic root replacement in high-risk women with
MFS has been shown to reduce the risk of complications
during pregnancy; prophylactic surgery for women desiring
pregnancy has been suggested if the diameter of the ascend-
ing aorta is >45 mm.10 Three women transferred their care
to our unit during pregnancy, and it is not clear what, if any,
pre-pregnancy counselling they had received. Four of the five
women who developed cardiac complications during preg-
nancy did not have pre-pregnancy counselling, highlighting
the need to raise awareness of issues of heart disease and
pregnancy among professionals and patients alike.
Two women developed impaired LV function. The path-
ogenesis of MFS-related LV dysfunction is poorly under-
stood. It has been suggested that mutations in the FBN1
gene may cause structural or functional abnormalities in
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the myofibrils, which may subsequently lead to impairment
of myocardial contractility.15
Apart from the 50% risk of having MFS, there appears
to be no consistent finding in the literature of an adverse
effect on the baby. There may be an increased chance of
SGA, but this is not a major effect and is unlikely to be
judged a contraindication to pregnancy. In our series, the
more fully expressed the phenotype, the smaller the baby,
although this was not a very strong trend. The increased
rate of SGA in our study may result from the current uni-
versal recommendation that women with MFS should be
prescribed beta-blockers for aortic root protection (in
non-pregnant patients they have been shown to have a small
impact on the rate of growth of the aortic root).2,22–24 In
our study beta-blockers were taken throughout 26 of 29
pregnancies: three women declined them because of their
inability to tolerate the side effects. The balance between
safeguarding the prognosis for the mother and the avoid-
ance of fetal growth restriction would require long-term
follow-up to investigate this fully. This emphasises the
importance of prospective multicentre registries for rare
conditions such as MFS for the determination of optimal
management policies. Currently most studies such as ours
are retrospective in nature: although data may have been
collected prospectively, the investigator decides which
analyses to perform after data collection. In future it
should become mandatory for prognosis research to have a
registered study protocol outlining the aims and detailing
the methods of data collection and statistical analysis that
will be used. Study registration and the publication of
analytical and study protocols may also help to improve
the quality of future studies.29
Conclusion
Pregnancy in women with MFS continues to be associated
with significant rates of maternal, fetal, and neonatal com-
plications. Our data emphasise the importance of careful
surveillance, jointly by obstetricians and cardiologists, of
both mother and fetus. The risk of aortic dissection should
be discussed in detail with the patient prior to conception,
and women should be carefully counselled about the need
to be seen urgently if they develop any significant chest
pain. Early intervention is vital in cases of dissection or
rapid dilatation of the aortic root.
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